HC Wainwright Reaffirms “Buy” Rating for Genmab A/S (NASDAQ:GMAB)

HC Wainwright reaffirmed their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a research note released on Tuesday morning, Benzinga reports. The firm currently has a $50.00 price target on the stock.

A number of other research firms have also weighed in on GMAB. BTIG Research upped their target price on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a buy rating in a research note on Thursday, June 27th. Truist Financial upped their target price on shares of Genmab A/S from $50.00 to $53.00 and gave the stock a buy rating in a research note on Tuesday, June 4th. Finally, Royal Bank of Canada upgraded shares of Genmab A/S from a sector perform rating to an outperform rating in a research note on Monday, July 15th. Three analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Genmab A/S presently has an average rating of Hold and a consensus target price of $49.50.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB opened at $27.02 on Tuesday. The firm has a market capitalization of $17.87 billion, a PE ratio of 22.52, a price-to-earnings-growth ratio of 1.01 and a beta of 0.97. The firm’s 50-day moving average is $26.64 and its two-hundred day moving average is $28.16. Genmab A/S has a 1 year low of $24.53 and a 1 year high of $39.53.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds have recently added to or reduced their stakes in GMAB. International Assets Investment Management LLC purchased a new position in Genmab A/S in the fourth quarter valued at approximately $393,000. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of Genmab A/S in the fourth quarter valued at approximately $216,000. M&T Bank Corp boosted its holdings in shares of Genmab A/S by 87.8% in the fourth quarter. M&T Bank Corp now owns 15,432 shares of the company’s stock valued at $492,000 after acquiring an additional 7,213 shares during the period. Vestmark Advisory Solutions Inc. boosted its holdings in shares of Genmab A/S by 28.5% in the fourth quarter. Vestmark Advisory Solutions Inc. now owns 35,656 shares of the company’s stock valued at $1,135,000 after acquiring an additional 7,905 shares during the period. Finally, Principal Securities Inc. acquired a new stake in shares of Genmab A/S in the fourth quarter valued at approximately $77,000. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.